摘要
目的:探讨青海地区进展期藏族胃癌患者胸苷酸合成酶增强子(TSER)、ERCC1基因、基因多态性以及mRNA表达意义。方法:选取2013年6月至2015年12月在青海大学附属医院就诊的210例晚期胃癌患者作为调查组,并在完成治疗后跟踪访问。TSER、ERCC1基因多态性均采用PCR-RFLP的方法进行检验。根据结果分析胃癌基因的多态性与临床病理因素的关系。ERCC1 mRNA的表达情况用(RT)-PCR的方法进行检测,在治疗之后进行跟踪访问。分析ERCC1 mRNA表达与临床治疗的总生存率和总反应率以及基因多态性的关系。结果:青海地区进展期胃癌患者C/C型ERCC1基因频率54.2%,C/T型ERCC1基因频率42.7%,T/T型ERCC1基因频率5.6%。ERCC1 mRNA表达情况与临床治疗中影响病理的因素均无相关性,ERCC1 mRNA与ERCC1基因多态性无相关性。结论:青海地区进展期藏族胃癌患者的TSER基因以3R/3R型高表达;ERCC1基因多态性以C/C型高表达;ERCC1、TSER基因多态性与进展期胃癌临床病理参数均无相关性;进展期藏族胃癌患者ERCC1 mRNA的高表达与ERCC1基因多态性无相关性。
Objective To discuss progress in Qinghai Tibetan Thymidylate synthase enhancer in patients with gastric cancer （TSER）, ERCC1 polymorphism of genes, gene expression and mRNA studies. Methods 210 cases of advanced gastric cancer were enrolled as required to complete the treatment and follow-up. TSER, ERCC 1 gene polymorphism were tested using PCR-RFLP method. Analysis of gastric cancer is based on the results of gene polymorphism and clinical pathological factors in relations. The expression of ERCC 1 mRNA was detected by RT- PCR, and tracking access after treatment. Analyzing the relationship among ERCC1 mRNA expression, clinical treatment of overall survival, total response rates and gene polymorphism. Results In patients with advanced gastric C/C in Qinghai ERCC1 gene frequency was 54.2%, C/T frequency was 42.7%, T/T ERCC1 gene frequency was 5.6%. ERCC1 mRNA expression and clinical effect in the treatment of pathological factors were not related, ERCC1 mRNA and gene ERCC1 polymorphism had no relevance. Conclusions Progress in Qinghai Tibetan TSER gene is highly expressed type 3R/3R in patients with gastric cancer. ERCC1 gene polymorphisms with type C/ C is overexpressed. ERCC1, TSER gene polymorphism and clinicopathologic parameters in advanced gastric is not related. Extension of Tibetan ERCC1 mRNA in gastric cancer patients expression has no association with ERCC1 gene polymorphism.
出处
《实用医学杂志》
CAS
北大核心
2017年第8期1255-1257,共3页
The Journal of Practical Medicine
基金
国家自然科学基金资助项目(编号:81560449)
